CLINICAL_TRIALS
trial_result
· 2025-09-03
Clinical Trial Update: Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention [Phase 4]
Summary
Pfizer completed a Phase 4 safety and tolerability study of daily rimegepant for episodic migraine prevention, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Migraine, Episodic Migraine | Phase 4 | Status: COMPLETED | Results posted: 2025-09-03